The use of psychedelics in Psychiatry – an interview with Dr James Rucker

02/03/2020

The use of psychedelics in Psychiatry: As our understanding of the causes of mental illness has developed, a growing number of pharmacological and non-pharmacological interventions have shown potential as novel treatments. While some of these remain experimental, others are emerging into routine clinical practice in the UK and around the world.

Drawing on recent exciting research findings, many of these interventions shine a new light on the causes and pathologies associated with psychiatric illnesses and are paving the way towards the future of psychiatry. From psychedelics to gut microbiome, Dr James Rucker explains the history and science behind using psilocybin, ketamine, MDMA, cannabis, transcranial magnetic stimulation, triple chronotherapy, and gut microbiome to treat psychiatric disorders.

The use of psychedelics in Psychiatry – an interview with Dr James Rucker:

 

Dr James Rucker also runs a two day masterclass course on this subject at Maudsley Learning. You can book this course here.

Dr Rucker is a Consultant Psychiatrist and a Senior Clinical Lecturer in mood disorders and psychopharmacology at the Centre for Affective Disorders at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London (UK). He will be running this course alongside his colleague, Professor Allan Young who holds the Chair of Mood Disorders at King’s College London where he is also Director of the Centre for Affective Disorders.

This course will cover topics such as psilocybin, ketamine, MDMA, cannabis, transcranial magnetic stimulation, triple chronotherapy, and gut microbiome.